CN1209113C - Tincture for treating psoriasis - Google Patents
Tincture for treating psoriasis Download PDFInfo
- Publication number
- CN1209113C CN1209113C CN 03134498 CN03134498A CN1209113C CN 1209113 C CN1209113 C CN 1209113C CN 03134498 CN03134498 CN 03134498 CN 03134498 A CN03134498 A CN 03134498A CN 1209113 C CN1209113 C CN 1209113C
- Authority
- CN
- China
- Prior art keywords
- tincture
- psoriasis
- skin
- present
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a tincture for treating psoriasis, which has the essential technical scheme that the tincture is prepared from the following materials according to the weight percent: 10 to 20% of salicylic acid, 1 to 3% of chlorpheniramine maleate, 10 to 30% of glycerol, 0.1 to 0.2% of sodium bisulfite and 50 to 75% of alcohol of which the concentration is from 60% to 70%. The present invention has high penetration capacity and has the characteristics of killing bacteria, alleviating itch, removing psoriasis, removing impairment and necrotic tissues, activating normal tissues to regenerate and recovering the normal structure and the normal function of the skin. The curative ratio respectively reaches 95% and 83.5% on psoriasis vulgaris and pustula psoriasis. Moreover, the present invention has no toxic or side effects and easy use.
Description
Technical field
The present invention relates to the dermopathic medicine for external use of a kind of treatment silver bits, especially relate to the psoriatic tincture of a kind of treatment.
Background technology
Psoriasis is common multiple dermatosis, and it is the chronic skin inflammation that turns to primary symptom with paroxysmal skin pruritus and skin lichen, and psoriasis accounts for 2/1000ths in China's generaI investigation population; Hospital Attached To Xuzhou Medical Institute's department of dermatologry has been investigated more than 100 ten thousand people in 1975 in Xuzhou Area, and the sickness rate in natural crowd is 0.229%; Having the scholar to add up national total prevalence rate in 1984 is 0.123%; Sickness rate can be up to 3% among some regional natural crowd abroad.The medical worker has carried out many-sided research to the psoriasis cause of disease, and is all relevant with the psoriasis generation as heredity, infection, dysbolismus, psychic trauma, immunologic function disorder, environmental stimuli etc., so think a kind of disease of controlled by multiple genes.Clinical practice, treatment psoriasis medicine external be better than taking orally, the tincture curative effect is better than other dosage forms again in the external used medicine.There are some defectives in the psoriatic external-use tincture of the treatment of prior art, or the single weak curative effect of composition, or is reluctant to use because of the medicine local excitation causes patient's pain.
According to the disclosed application number of Chinese patent is the patent application of 95111402.6 " medicine for psoriasis " by name, this invention comprises dexamethasone and menthocamphorate, wherein dexamethasone is the 17-hydroxy-11-dehydrocorticosterone medicine, it increases slightly the pore of skin, hair increases, destroy the local skin physiological function, medically very prudent, psoriatic treatment is also made us being difficult to satisfied to inferior medication.Tincture of the present invention does not contain hormone, and penetration is strong, can thoroughly kill the pathogenic bacterium of top layer and deep layer, thereby improves the resistance and the immunity of local skin.
Summary of the invention
The objective of the invention is for overcoming disadvantages of background technology, and a kind of good effect is provided, alleviates the psoriatic tincture of a kind of treatment that local skin stimulates.
The object of the present invention is achieved like this: its component and percetage by weight are as follows:
Salicylic acid 10-20%
Chlorphenamine maleate 1-3%
Glycerol 10-30%
Sodium sulfite 0.1-0.2%
60%-70% ethanol 50-75%
The preferred weight percent of each component of the present invention is as follows:
Salicylic acid 10-15%
Chlorphenamine maleate 1.5-2%
Glycerol 10-20%
Sodium sulfite 0.1-0.2%
60%-70% ethanol 60-74%
The optimum weight percent of each component of the present invention is as follows:
Salicylic acid 12.5%
Chlorphenamine maleate 2%
Glycerol 12%
Sodium sulfite 0.15%
60%-70% ethanol 73.35%
The present invention mainly is made up of salicylic acid, chlorphenamine maleate, glycerol and 60%-70% ethanol, and salicylic acid can dissolve squama (horn cell), comes off after making cell simultaneously and squama being separated, and anticorrosion, bactericidal action is arranged; Chlorphenamine maleate can discharge antihistaminic, makes the blood capillary of expansion recover normal, and tissue fluid is no longer oozed out, and can reach the itching relieving effect; Glycerol can improve the viscosity of preparation, makes medicine be stranded in the affected part and prolongs its local drug effect, simultaneously because the lubrication of glycerol can relax the zest of ethanol to skin; Concentration is the ethanol of 60%-70%, and penetration is strong, can distend the blood vessels, and blood circulation is accelerated, and impels metabolism, activates the regeneration of cambium then.The psoriatic tincture of a kind of treatment that the present invention mainly is made up of salicylic acid, chlorphenamine maleate, glycerol and 60%-70% ethanol; it can dissolve squama (horn cell) simultaneously can make cell separate with squama it is come off; dissolved silver-colored bits can form the crust film before coming off; cambium regeneration below the protection; after growing well, cambium promptly finishes repair function; protecting film comes off voluntarily, can kill fungus simultaneously.
The present invention was through the clinical observation in more than 20 years, accumulation case 1000 many cases, in recent years complete case is selected 298 examples and carried out statistical procedures, find that said preparation is respectively 95% and 83.5% to homeliness type and psoriasis pustulosa cure rate, surpassed psoriatic external Chinese patent medicine of other treatment and Western medicine.
Advantage of the present invention is: the present invention has sterilization, antipruritic, the sick characteristics that undermine slough, activation normal structure new life, recover skin normal configuration and normal desquamation function of removal, homeliness type and psoriasis pustulosa cure rate are respectively 95% and 83.5%, and there is not toxicity, easy to use.
The specific embodiment
Embodiment 1
The component and the percetage by weight of prescription are as follows:
Salicylic acid 14.5% chlorphenamine maleate 2.5%
Glycerol 14% sodium sulfite 0.1%
60%-70% ethanol 68.9%
Preparation method: get the distilled water heated and boiled, cool, prepare 60% solution with ethanol, standby.
Above-mentioned salicylic acid, chlorphenamine maleate and glycerol are added in the alcoholic solution of concentration 60%-70%, stirring makes dissolving, the adding percetage by weight is 0.1% sodium sulfite, and full dose is supplied with the 60%-70% alcoholic solution in the dissolving back, and filtration, packing promptly get (40 milliliters every bottle)
Embodiment 2
The component and the percetage by weight of prescription are as follows:
Salicylic acid 15.5% chlorphenamine maleate 1.5%
Glycerol 15% sodium sulfite 0.2%
60%-70% ethanol 67.8%
Preparation method: get the distilled water heated and boiled, cool, prepare 60% solution with ethanol, standby.
In above-mentioned salicylic acid, chlorphenamine maleate and glycerol adding 60%-70% alcoholic solution, stir and make dissolving, the adding percetage by weight is 0.2% sodium sulfite, and full dose is supplied with 60% alcoholic solution in the dissolving back, and filtration, packing promptly get (40 milliliters every bottle)
Embodiment 3
The component and the percetage by weight of prescription are as follows:
Salicylic acid 12.5% chlorphenamine maleate 2%
Glycerol 12% sodium sulfite 0.15%
60%-70% ethanol 73.35%
Preparation method: get the distilled water heated and boiled, cool, prepare 60% solution with ethanol, standby.
It is in the alcoholic solution of 60%-70% that above-mentioned salicylic acid, chlorphenamine maleate and glycerol are added concentration, stirring makes dissolving, the adding percetage by weight is 0.15% sodium sulfite, dissolving back is that the alcoholic solution of 60%-70% is supplied full dose with concentration, and filtration, packing promptly get (40 milliliters every bottle).
The present invention has made skin Kang Jing tincture acute toxicity test and long term toxicity test by Xi'an Jiaotong University Medical College's clinical pharmacology institute.
The acute toxicity test of skin Kang Jing tincture: skin Kang Jing tincture is 8ml/kg to rabbit percutaneous drug delivery consumption every day, the slight redness of animal skin appearance in 1-24 hour after the administration, recover next day normal, no animal dead phenomenon takes place in 7 days, illustrate that skin Kang Jing tincture has slight zest to rabbit skin, does not have tangible acute toxicity.
Skin Kang Jing tincture long term toxicity test: the long term toxicity test result of 3 months, 6 months skin of back coatings of skin Kang Jing tincture rat shows, rat generally in order during the administration, occur slight red and swollen behind the coating of individual animal back, recovered normal in second day, illustrate that the psoriatic tincture of treatment has slight zest to rat skin.Rat during administration each dosage treated animal generally in order, appetite and body weight etc. are all no abnormal, blood and blood biochemical are learned index and difference, free of toxic effects are not occurred, recover normal after the drug withdrawal, routine urinalysis and electrocardiogram are no abnormal, organ coefficient is also no abnormal, and system dissects and histopathological examination does not find that the pathologic of skin Kang Jing tincture causes harm and uses.Illustrate that this medicine do not find toxic reaction in the rat long term toxicity test, every index is normal convalescent period after the drug withdrawal, does not also have the delayed toxicity reaction.The animal safety consumption is 24ml/kg/ day.
Claims (3)
1, the psoriatic tincture of a kind of treatment is characterized in that its component and percetage by weight are as follows:
Salicylic acid 10-20% chlorphenamine maleate 1-3%
Glycerol 10-30% sodium bisulfate 0.1-0.2%
60%-70% ethanol 50-75%.
2, the psoriatic tincture of a kind of treatment according to claim 1 is characterized in that its component and percetage by weight are as follows:
Salicylic acid 12-15% chlorphenamine maleate 1.5-2%
Glycerol 12-25% sodium sulfite 0.1-0.2%
60%-70% ethanol 60-74%.
3, the psoriatic tincture of a kind of treatment according to claim 1 is characterized in that its component and percetage by weight are as follows:
Salicylic acid 12.5% chlorphenamine maleate 2%
Glycerol 12% sodium sulfite 0.15%
60%-70% ethanol 73.35%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03134498 CN1209113C (en) | 2003-08-15 | 2003-08-15 | Tincture for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03134498 CN1209113C (en) | 2003-08-15 | 2003-08-15 | Tincture for treating psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488351A CN1488351A (en) | 2004-04-14 |
| CN1209113C true CN1209113C (en) | 2005-07-06 |
Family
ID=34154510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03134498 Expired - Fee Related CN1209113C (en) | 2003-08-15 | 2003-08-15 | Tincture for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1209113C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1297272C (en) * | 2005-02-25 | 2007-01-31 | 王效山 | New use of chlophenamine maleate |
| CN112641923A (en) * | 2020-12-24 | 2021-04-13 | 烟台心舒医药科技有限公司 | Novel composition for treating psoriasis |
-
2003
- 2003-08-15 CN CN 03134498 patent/CN1209113C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1488351A (en) | 2004-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2099462B1 (en) | Pharmaceutical preparation for the treatment of inflammatory diseases of the urogenital tract | |
| CN101573130B (en) | Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy | |
| CN107362141B (en) | A kind of Anefrin Nasal Spray and preparation method thereof | |
| KR101800851B1 (en) | Local anesthesia pain-relieving time-delay angent | |
| CN100431547C (en) | A triptolide composite preparation for treating osteoarthritis by joint intracavity injection | |
| CN1209113C (en) | Tincture for treating psoriasis | |
| WO1996032117A1 (en) | Bioactive concentrate, its producing method and certain drug compositions containing also chondroitin sulphate | |
| CN1251736C (en) | Chinese medicinal infusion for treating shingles, parotitis acute mamitis and its manufacturing method | |
| CN112521389B (en) | Medicament and method for promoting wound healing | |
| DE102017113203A1 (en) | Medical use of potassium hydroxide | |
| CN104971349B (en) | A kind of externally used compound preparation | |
| CN1398861A (en) | Prepn and application in preparing medicine of Fraxinus general coumarin | |
| CN1931191A (en) | Medicine composition for treating senile cataract in initial stage and its prepn process | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| Iliakis et al. | Is medical ozone safe when injected intra articularly | |
| WO2019096144A1 (en) | Use of pientzhuang and preparation thereof in treatment of cerebral stroke sequelae | |
| CN1124159A (en) | Cobra venom injection and its producing method | |
| RU2827071C1 (en) | Agent for treating degenerative processes of musculoskeletal system | |
| CN1112199C (en) | Exterior-applied medicine for treating dermatopathy | |
| CN1239180C (en) | Medicine for treating piles | |
| CN108606985A (en) | It is a kind of to be used to treat compound salicylic acid lotion of Keratotic tinea hand or pedis and preparation method thereof | |
| CN1232257C (en) | Application of N-acetylglucosamine in the preparation of medicine for treating and contrlling non specific inflammation due to physicochemical factor | |
| Gunawan et al. | Effects of Ozonized Aloe Vera Oil on Full-Thickness Excision Wound Healing: In Vivo Study | |
| CN1927352A (en) | Externally used traditional Chinese medicine preparation for treating nasal mucosa erosion and nosebleed and its preparation method | |
| CN1739665A (en) | Method of preparing active medicinal matter of lignin from broad-leaved tree and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050706 |